Sunshine on Europe: impact of recent EFPIA and EU guidelines on publication planners. Susan Scott, PhD, CMPP Director, Scott Pharma Solutions Ltd

Transcription

1 Sunshine on Europe: impact of recent EFPIA and EU guidelines on publication planners Susan Scott, PhD, CMPP Director, Scott Pharma Solutions Ltd

2 Disclaimer As an independent consultant, the views expressed in this presentation are my own and do not necessarily reflect the views of the conference organisers 2

3 3 Transparency

4 Agenda Evolution of data transparency Scientific publications & congress abstracts & presentations Trial registration, Results posting Clinical study report & clinical summary public release Individual subject data release, Lay summaries Response from pharmaceutical industry & industry organisations Public policies New guidelines GPP3 Evolution of financial payments transparency Sunshine Act EfPIA Disclosure Code New practices Publication & disclosure plan Impact on protocol, QC processes 4

5 20th century Publication Outlets Clinical study report Only to regulatory agency Congress abstract & poster 5

6 Publication outlets Clinical study report Only to regulatory agency Congress abstract & poster 6

7 European Medicines Agency policy, June 2014 Mandatory posting of results Interventional clinical trials ending after 21 July 2014 Results must be posted on EudraCT within 12 mo (adult) or 6 mo (paediatric) of study completion Using defined data set Interventional clinical trials ending before 21 July 2014 Results must be posted retrospectively Using defined data set and/or summary Different timeframes dependent on type of trial & date of completion ALL interventional trials whether drugs approved or not 7

8 European Medicines Agency policy, October 2014 Publication of clinical data Make publicly available with redaction of personal identifying and commercially confidential information (CCI): Clinical overviews Clinical summaries Clinical study reports with Protocols & amendments Sample case report form Documentation of statistical methods Individual patient data (IPD) When decision taken on MAA submitted by centralised procedure (approval or withdrawal) 8

9 9 July 2013

10 Current disclosure outlets From 2014/ 2015 Lay Summaries Protocol & amendments CSR synopses Individual patient data (IPD) Clinical study report Congress abstract & poster 10

11 11 Discrepancy between published articles and trial registry information

12 From: Comparison of Registered and Published Primary Outcomes in Randomized Controlled Trials! Sylvain Mathieu, MD; Isabelle Boutron, MD, PhD; David Moher, PhD; Douglas G. Altman, DSc; Philippe Ravaud, MD, PhD JAMA. 2009;302(9): doi: /jama " 12

13 13 PLoS Med Dec;10(12):e ; discussion e doi: /journal.pmed Epub 2013 Dec 3.

14 14 PUBLICATION POLICIES

15 15

16 16

17 17 Sets out 10 Good Publication Practice principles for company-sponsored medical research Endorses sharing full study reports and appropriately anonymised individual subject data with qualified researchers on request Spells out research which should be published, including non-interventional studies Expands guidance on interpretation of ICMJE authorship criteria & addresses common authorship issues Clarifies appropriate author payments Expands on role of medical writers

18 DeTora L, Foster C, Skobe C, Yarker Y, Crawley FP. Int J Clin Pract, September 2015, 69, 9, A supportive and well-organised plan ensuring that the research and its results are communicated clearly to the scientific and healthcare communities as well as the general public is essential 18

19 From 2015 Provide redacted CSR, lay summaries, IPD Appears EU-CTR Post results on ct.gov, EU-CTR Register CT.gov 12 mo Paed 6 mo First Pat In Last Pat Out D/base Lock Tab Fig List Final Clin Study Report Burden of disease congress abstract Method/ population congress abstract Poster/ talk Poster/ talk 1 st results Congress abstract Poster/ talk Press release? Publication & disclosure plan 19 Primary manuscript Secondary manuscript(s)

20 20 FINANCIAL TRANSPARENCY

21 Physician Payments Sunshine Act - effective Apr 2013 Summary Data for

22 Obliges member companies to disclose direct or indirect Transfers of Value to or for the benefit of an HCP Donations or grants Events costs Service or consultancy fees To individual named recipient R&D costs reported on aggregate basis Annual reporting Report on company or government/ association website 22

23 Plan Standardise processes Communicate 23

24 PLAN PROTOCOL Prepare protocol considering it WILL become public Clear primary endpoint & timeframe Restrict number of secondary endpoints Prepare protocol with Company Confidential Information redacted 24

25 PLAN PUBLICATION & DISCLOSURE PLAN Prepare plan before study recruitment Plan key scientific content for each congress abstract/ poster/ oral & manuscript trial registries & results database submission press release Data availability & timelines Authors, contributors Target journals (with contingency) & congresses Review & Approval Heads of Publications, Disclosure Team, Med Affairs, Clin Dev, Reg Affairs, Data Mgmt & Stats, Compliance, Public Affairs, Chief Medical Officer NOT Sales/ Marketing 25

26 STANDARDISE QC PROCESSES Identify one results document as core Final tables, figures & listings? 4mo after study completion ( paediatric trials) 10 mo after study completion (adult trials) Same data in CSR, Results registries, Congress abstracts, posters &/or oral presentations, Primary manuscripts, Clinical overviews & clinical summaries Review vs core document Draft trial & results registrations Draft scientific manuscripts & congress materials Ensure study identifier(s) included in ALL publications 26

27 STANDARDISE PROCESSES Record costs/ publication project Medical writing/ editing Journal open access Copyright permission Congress abstract submission, attendance expenses Named individual reporting vs aggregate reporting part of clinical research? 27

28 COMMUNICATE PUBLICATION & DISCLOSURE PLAN Present to: Project team Key internal sponsors eg Clin Dev, Med Affairs, Stats & Data Mgmt External study investigators Co-development partner 28

29 COMMUNICATE PUBLICATION & DISCLOSURE PROGRESS Use Publication Management software Eg DataVision, PubsHub, PubStrat Controlled access to all Publication & Disclosure team members Include Disclosure tasks in project activities Choose Medical Communications vendor with user capability 29

30 COMMUNICATE PUBLICATION & DISCLOSURE PLANNING MEETINGS Regular F2F/ TC/ videolink Members Disclosure rep, publication manager, medical writer(s) of CSR & publications, Med Affairs, Clin Dev, Reg Affairs, Data Management & Stats, Compliance Review progress of Publication & Disclosure plan timeframe, key content, issues & solutions For trials on products under joint development Key staff from development partners 30

31 31 Change of mindset

32 32 Transparency

33 33

34 34 THANK YOU